DDX5 and neoplasm: IHC of DDX5 showed a higher number of nuclei with “diffuse”/less intense DDX5 staining in sorafenib-treated tumors than in peri-tumor (Fig. 3E), consistent with reduced DDX5 mRNA levels in sorafenib-treated tumors (Fig. 3F, H), but not in the peri-tumoral tissue (Fig. 3G, H).